What is the difference between Foxo4-DRI and Livagen?

Foxo4-DRI: D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells" Livagen: Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Is Foxo4-DRI FDA approved?

Foxo4-DRI is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Livagen FDA approved?

Livagen is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Foxo4-DRI administered in research settings?

In research settings, Foxo4-DRI is typically administered via the intravenous or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Livagen administered in research settings?

In research settings, Livagen is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Foxo4-DRI vs Livagen

Peptide Comparison

Foxo4-DRI vs Livagen

Name: Foxo4-DRI vs Livagen — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

Foxo4-DRI

Foxo4-D-Retro-Inverso

LongevityNot EvaluatedResearch Only

Half-life: Unknown

13 providers listed

Full Foxo4-DRI profile →

Livagen

Lys-Glu-Asp-Glu

LongevityNot EvaluatedResearch Only

Half-life: Unknown

2 providers listed

Full Livagen profile →

Bottom line

Foxo4-DRI is carried by more providers on PeptideBase (13 vs 2); otherwise the two are closely matched on the measures we track.

Quick Verdict

Foxo4-DRI

Evidence

Preclinical

Livagen

Evidence

Review-level

Which One Should You Choose?

Your goal	Better option
More provider options (13 vs 2)	Foxo4-DRI

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Foxo4-DRI

Livagen

Mechanism Family

Longevity & Cellular

Half-life

Unknown

FDA Status

not evaluated

Admin Routes

intravenous, subcutaneous

subcutaneous, intramuscular

Availability

Research Only

Providers

13 listed

2 listed

Avail. Notes

Senolytic D-retro-inverso Foxo4 peptide (de Keizer lab, Netherlands). Eliminates p21-positive senescent cells. No FDA approval, no IND or NDA. Novel research compound only.

Russian liver peptide bioregulator (Lys-Glu-Asp-Gly) from Khavinson Institute. Studied for aging and hepatic function. No FDA approval, no NDA or IND. Research chemical in US.

Research Evidence

Foxo4-DRI

PreclinicalReview · 3 key studies · most recent 2026

Livagen

Review-levelReview · 2 key studies · most recent 2022

Research Citations

Foxo4-DRI

Animal2017 · Cell

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Review2026 · Naunyn Schmiedebergs Arch Pharmacol

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigat…

Animal2021 · EBioMedicine

Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-…

Livagen

Review2022 · International Journal of Molecular Sciences

Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies

Review2020 · Stem Cell Reviews and Reports

Short Peptides in the Treatment of Age-Related Diseases

About Foxo4-DRI

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

Research Areas

senescent cell clearancetissue rejuvenationhealthspan extensionsenolytic

About Livagen

Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Research Areas

liver cell regenerationhepatoprotectionimmune restoration via liverchromatin activation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Foxo4-DRI

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Livagen

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Foxo4-DRI

$24.44/mg

$20.50 – $26.50 range

10 vendors

View price index →Find providers →

Livagen

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Foxo4-DRI

13 listed

Browse directory →

Providers offering

Livagen

2 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 22, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Foxo4-DRI vs Livagen — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/foxo4-dri/livagen

https://peptidebase.io/peptides/compare/foxo4-dri/livagen Methodology License Download JSON Download CSV